SEURO targets Europe’s 50 million multimorbid patients to proactively self-manage and offset the EU’s annual €700 billion cost of chronic disease management. SEURO aims to evaluate key factors to prepare organisations, localities and regions across the EU to scale, sustain and transfer the people-centred, digital integrated care platform ProACT (developed and successfully tested at proof of concept level under Horizon 2020, PHC-25-2015, Grant No. 689996). Research will aim to advance 3 novel implementation support tools. These consist of a transferability self-assessment tool (ProTransfer) to assess preparedness for solution transfer; a behavioural change framework (ProBCF) to optimise a solution to people’s needs; and an artificial intelligence (AI) prediction model (ProInsight) to assess the impact of a solution on health system performance. Effective Implementation Hybrid Trials (720 older adults in total, with associated care/support actors) will be carried out with ProACT within health services (Ireland, Belgium Sweden to measure platform effectiveness), with embedded process evaluations to understand the process for successful ‘real world’ implementation. Participants will have at least two of the following: cardiovascular disease (excluding Stroke), a respiratory condition and diabetes. Commercial potential will be validated during the project supported by an exploratory trial (Italy) to evaluate the impact of SEURO in facilitating a procurement process for healthcare service providers aiming to implement ProACT. SEURO engages a multidisciplinary EU consortium of 4 public and 8 private organisations (including one of the world's leading ICT companies, the largest home care provider and 2 EU service provider and technology networks). Partners have a successful collaborative track record. Together we are in a strong position to consolidate EU research assets into a new comprehensive approach for the scale-up and transfer of digital integrated care solutions.